In particular, 18 patients (11 cHL, six T‐cell lymphoma, one gray zone lymphoma) were infused with anti‐CD30 CAR‐T cells at a median of 22 days (range 16–44) after ASCT. The gene discussed is TNFRSF8; the disease is classic Hodgkin lymphoma.